Please assess the completion status of the following clinical trial:

Trial Title: A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~F506-CL-0404 Part A~* Subject was ≤12 years of age at enrolment into study F506-CL-0403~* Subject received at least one dose of Modigraf in the F506-CL-0403 study~F506-CL-0404 Part B~* Subject received at least one dose of Modigraf in the F506-CL-0403 study~* Subject participated in F506-CL-0404 Part A~* Subject has continuously been dosed with Twice daily (BID) Modigraf since the End of Study Visit for Part A (ESVA) from F506-CL-0404 Part A~* Subject is stable and has had no dose changes in the preceding 2 weeks~Exclusion Criteria:~F506-CL-0404 Part A~* As all subjects included in this study conform to the exclusion criteria in study F506-CL-0403, hence no specific exclusion criteria are relevant for this study~F506-CL-0404 Part B~* There are no specific exclusion criteria for this study

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Part A: Heart Transplant (Tacrolimus granules) (Type: EXPERIMENTAL): In Part A of the study, participants who are heart transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
- Part A: Liver Transplant (Tacrolimus granules) (Type: EXPERIMENTAL): In Part A of the study, participants who are liver transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
- Part A: Kidney Transplant (Tacrolimus granules) (Type: EXPERIMENTAL): In Part A of the study, participants who are kidney transplant recipients receive tacrolimus granules-based immunosuppressive regimen twice daily for a maximum of 1 year or until commercial availability of tacrolimus granules in the participant's country.
- Part B: All Participants (Tacrolimus capsules) (Type: EXPERIMENTAL): In Part B of the study, participants who are heart, kidney or liver transplant recipients and who are converted from tacrolimus granules-based immunosuppression regimen, receive tacrolimus capsules twice daily for 1 month and thereafter receive commercially available tacrolimus capsules.

Based on this trial design, predict the completion outcome and termination type (if applicable).